|

Spevatamig (PT886) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Phanes Therapeutics1

Indications

  • Gastric or Gastroesophageal Junction Adenocarcinoma1
  • Biliary Tract Cancer (BTC)1
  • Pancreatic Ductal Adenocarcinoma1
  • Cancer1

Duarte, California1 trial

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.